PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES

被引：2
|
作者：
Rosell, R. [1 ]
Gettinger, S. [2 ]
Bazhenova, L. A. [3 ]
Langer, C. J. [4 ]
Salgia, R. [5 ]
Gold, K. [6 ]
Shaw, A. T. [7 ]
Dorer, D. J. [8 ]
Kerstein, D. [9 ]
Camidge, D. R. [10 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol ICO Badalona, Med Oncol Serv, Badalona, Spain
[2] Yale Univ, Sch Med Med Oncol, Thorac Oncol Program, New Haven, CT USA
[3] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Chicago, Med Ctr, Thorac Oncol, Chicago, IL 60637 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[8] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA 02139 USA
[9] ARIAD Pharmaceut Inc, Clin Res, Cambridge, MA 02139 USA
[10] Univ Colorado, Ctr Canc, Thorac Oncol, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv050.3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
99O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
    Leal, T.
    Wakelee, H.
    Reckamp, K.
    Waqar, S.
    Patel, S.
    Blumenschein, G.
    Neal, J.
    Harrow, K.
    Holzhausen, A.
    Liang, C.
    Dukart, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S156 - S156
  • [22] Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
    Solomon, Benjamin
    Bauer, Todd
    Mok, Tony
    Liu, Geoffrey
    Mazieres, Julien
    de Marinis, Filippo
    Goto, Yasushi
    Kim, Dong-Wan
    Wu, Yi-Long
    Dvorkin, Mikhail
    Jassem, Jacek
    Lopez-Lopez, Froylan
    Soo, Ross
    Polli, Anna
    Dall'O, Elisa
    Iadeluca, Laura
    Toffalorio, Francesca
    Felip, Enriqueta
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
    Salgia, Ravi
    Solomon, Benjamin J.
    Shaw, Alice Tsang
    Camidge, D. Ross
    Evans, Tracey L.
    Kim, Dong-Wan
    Shi, Yuankai
    Han, Ji-Youn
    De Pas, Tommaso Martino
    Ou, Sai-Hong Ignatius
    Bartlett, Cynthia Huang
    Wilner, Keith D.
    Reisman, Arlene
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"
    Sullivan, Ivana
    Planchard, David
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1287 - E1292
  • [25] Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
    Leal, T.
    Wakelee, H.
    Reckamp, K. L.
    Chiappori, A.
    Oxnard, G. R.
    Waqar, S. N.
    Patel, S. P.
    Blumenschein, G. R.
    Neal, J. W.
    Harrow, K.
    Holzhausen, A.
    Selvaggi, G.
    Zhou, J.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1171 - S1172
  • [26] Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC)
    Wakelee, H.
    Reckamp, K. L.
    Leal, T. A.
    Patel, S. P.
    Blumenschein, G.
    Shum, E.
    Nieva, J.
    Oxnard, G.
    Sanborn, R. E.
    Waqar, S.
    Zeman, K.
    Dukart, G.
    Harrow, K.
    Liang, C.
    Holzhausen, A.
    Horn, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK plus ) advanced non-small cell lung cancer (NSCLC) in US clinical practice
    Krebs, M. G.
    Polito, L.
    Smoljanovic, V.
    Trinh, H.
    Crane, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK1) non-small cell lung cancer (NSCLC) patients (Pts)
    Reckamp, K. L.
    Lee, J.
    Huang, J.
    Proskorovsky, I.
    Reichmann, W.
    Krotneva, M.
    Kerstein, D.
    Huang, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
    Popat, S.
    Liu, G.
    Lu, S.
    Song, G.
    Samnotra, V.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
    Horn, L.
    Wu, Y-L.
    Reck, M.
    Liang, C.
    Tan, F.
    Harrow, K.
    Oertel, V.
    Dukart, G.
    Mok, T. S. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S116 - S116
12345